Free Trial

Innate Pharma (IPHA) Competitors

Innate Pharma logo
$2.20 +0.01 (+0.64%)
As of 11:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IPHA vs. DAWN, AKBA, OLMA, TYRA, TERN, TBPH, ARVN, ERAS, SNDL, and MLTX

Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), Theravance Biopharma (TBPH), Arvinas (ARVN), Erasca (ERAS), SNDL (SNDL), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Innate Pharma vs. Its Competitors

Day One Biopharmaceuticals (NASDAQ:DAWN) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Innate Pharma has lower revenue, but higher earnings than Day One Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Day One Biopharmaceuticals$131.16M5.83-$95.50M-$0.95-7.86
Innate Pharma$21.77M9.33-$53.53MN/AN/A

Day One Biopharmaceuticals has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Innate Pharma has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Innate Pharma's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Day One Biopharmaceuticals-50.63% -19.01% -16.99%
Innate Pharma N/A N/A N/A

In the previous week, Day One Biopharmaceuticals had 4 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Day One Biopharmaceuticals and 0 mentions for Innate Pharma. Day One Biopharmaceuticals' average media sentiment score of 0.39 beat Innate Pharma's score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Day One Biopharmaceuticals Neutral
Innate Pharma Neutral

88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Day One Biopharmaceuticals currently has a consensus price target of $25.29, suggesting a potential upside of 238.72%. Innate Pharma has a consensus price target of $6.50, suggesting a potential upside of 194.92%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Day One Biopharmaceuticals is more favorable than Innate Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Day One Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.00
Innate Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Day One Biopharmaceuticals beats Innate Pharma on 8 of the 15 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPHA vs. The Competition

MetricInnate PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$203.17M$3.42B$6.19B$10.78B
Dividend YieldN/A2.26%5.72%4.83%
P/E RatioN/A23.5529.8828.59
Price / Sales9.33270.54503.00189.86
Price / CashN/A44.5736.5560.64
Price / Book20.0410.4212.026.62
Net Income-$53.53M-$52.53M$3.32B$276.83M
7 Day Performance1.80%2.08%1.63%2.10%
1 Month Performance21.17%10.95%6.26%2.69%
1 Year Performance19.44%13.94%61.43%34.06%

Innate Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPHA
Innate Pharma
2.0555 of 5 stars
$2.20
+0.6%
$6.50
+194.9%
+13.5%$203.17M$21.77M0.00220Gap Up
DAWN
Day One Biopharmaceuticals
2.9446 of 5 stars
$7.19
-0.7%
$25.29
+251.7%
-48.6%$741.61M$131.16M-7.5760Upcoming Earnings
AKBA
Akebia Therapeutics
3.5051 of 5 stars
$2.78
+1.1%
$6.75
+142.8%
+87.4%$729.15M$160.18M-16.35430
OLMA
Olema Pharmaceuticals
3.1099 of 5 stars
$10.75
+1.7%
$23.33
+117.1%
-32.1%$725.47MN/A-5.4370
TYRA
Tyra Biosciences
2.2573 of 5 stars
$14.36
+6.2%
$31.86
+121.8%
-50.0%$720.58MN/A-8.0720
TERN
Terns Pharmaceuticals
3.9237 of 5 stars
$8.20
+0.6%
$15.49
+88.9%
+7.3%$713.22MN/A-7.8840News Coverage
Analyst Forecast
TBPH
Theravance Biopharma
2.4668 of 5 stars
$13.92
-0.5%
$23.00
+65.2%
+63.8%$704.55M$64.38M58.00110
ARVN
Arvinas
3.474 of 5 stars
$9.80
+3.6%
$16.29
+66.2%
-65.5%$694.53M$263.40M-9.70420Upcoming Earnings
High Trading Volume
ERAS
Erasca
2.8793 of 5 stars
$2.40
-0.4%
$3.71
+54.8%
-14.3%$683.65MN/A-5.33120
SNDL
SNDL
3.0569 of 5 stars
$2.48
-1.6%
$4.50
+81.5%
+3.3%$662.20M$671.81M-9.182,516
MLTX
MoonLake Immunotherapeutics
2.8909 of 5 stars
$10.66
+3.9%
$36.00
+237.7%
-79.7%$659.01MN/A-3.832Trending News

Related Companies and Tools


This page (NASDAQ:IPHA) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners